van de Griend R J, Tax W J, van Krimpen B A, Vreugdenhil R J, Ronteltap C P, Bolhuis R L
J Immunol. 1987 Mar 1;138(5):1627-33.
A small subpopulation (about 2%) of normal CD3+ human T lymphocytes lacks both CD4 and CD8 antigens. We have cloned these cells from peripheral blood lymphocytes (PBL) obtained from healthy individuals and from a patient with severe combined immunodeficiency. Six out of seven CD3+4-8-clones exert strong cytolytic activity against a variety of so-called NK-susceptible and -nonsusceptible tumor target cells. Their target cell specificity spectrum can virtually be as wide as that of CD3-NK cell-derived clones, with strong lytic capacity. Some of these clones also exert antibody-dependent cellular cytotoxicity (ADCC), a characteristic of NK cell-derived clones but not of CD3+4+ or CD8+ mature T cell-derived clones. Such CD3+ T cell clones do not express the CD16 (IgG Fc receptor) antigen, but as we demonstrate here, the CD16 antigen can be identified on CD3+4-8-clones. Both ADCC activity and CD16 antigen expression are lower in CD3+4-8- than in CD3- NK cell clones. Lytic activity of mature CD3+4+ or CD8+ and CD3- NK cell clones can be augmented, respectively, by anti-CD3 or anti-CD16 monoclonal antibodies (MAb), but that of CD3+4-8- clones are augmented by both MAb. Lytic activity of CD3+4+ or CD8+ clones is considerably enhanced after 3 hr of incubation with recombinant IL 2, as found for CD3- NK cells. Enhancement of lytic activity of allospecific CD3+4+ or CD8+ clones requires 18 hr of incubation. Thus, CD3+4-8-16+ cells share several features with CD3- NK cells. However, they express the CD3 antigen, which is characteristic for CD4+ or CD8+ mature T cells. Our results also indicate that although CD3+4-8- clones react with five preparations of anti-CD3 MAb tested, these clones do not express a classical CD3+/Ti alpha, beta antigen receptor complex. This is suggested by the finding that the CD3+4-8- clones do virtually not express the common epitope of the T cell receptor alpha, beta-chains as identified by the WT31 MAb. These CD3+4-8- lymphocytes may represent functionally mature lymphocytes of a distinct T cell subpopulation having a particular immune function.
一小部分（约2%）正常的CD3⁺人T淋巴细胞既缺乏CD4抗原也缺乏CD8抗原。我们已从健康个体和一名重症联合免疫缺陷患者的外周血淋巴细胞（PBL）中克隆出了这些细胞。7个CD3⁺4⁻8⁻克隆中有6个对多种所谓的NK敏感和不敏感肿瘤靶细胞具有强大的细胞溶解活性。它们的靶细胞特异性谱实际上可以与CD3⁻NK细胞衍生的克隆一样广泛，且具有强大的溶解能力。其中一些克隆还具有抗体依赖性细胞毒性（ADCC），这是NK细胞衍生克隆的特征，但不是CD3⁺4⁺或CD8⁺成熟T细胞衍生克隆的特征。此类CD3⁺T细胞克隆不表达CD16（IgG Fc受体）抗原，但正如我们在此证明的，CD16抗原可在CD3⁺4⁻8⁻克隆上被识别。CD3⁺4⁻8⁻克隆中的ADCC活性和CD16抗原表达均低于CD3⁻NK细胞克隆。成熟的CD3⁺4⁺或CD8⁺以及CD3⁻NK细胞克隆的溶解活性可分别通过抗CD3或抗CD16单克隆抗体（MAb）增强，但CD3⁺4⁻8⁻克隆的溶解活性可被两种MAb增强。与CD3⁻NK细胞一样，CD3⁺4⁺或CD8⁺克隆与重组IL-2孵育3小时后，其溶解活性会显著增强。同种异体特异性CD3⁺4⁺或CD8⁺克隆的溶解活性增强需要孵育18小时。因此，CD3⁺4⁻8⁻16⁺细胞与CD3⁻NK细胞具有一些共同特征。然而，它们表达CD3抗原，这是CD4⁺或CD8⁺成熟T细胞的特征。我们的结果还表明，尽管CD3⁺4⁻8⁻克隆与所测试的5种抗CD3 MAb制剂发生反应，但这些克隆不表达经典的CD3⁺/Tiα、β抗原受体复合物。这是由以下发现所提示的：CD3⁺4⁻8⁻克隆实际上不表达WT31 MAb所识别的T细胞受体α、β链的共同表位。这些CD3⁺4⁻8⁻淋巴细胞可能代表具有特定免疫功能的独特T细胞亚群中功能成熟的淋巴细胞。
